According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:
- Humacyte’s Durham, North Carolina facility failed to comply with good manufacturing practices, including quality assurance and microbial testing;
- the Food and Drug Administration’s (“FDA”) review of the Biologics License Application (“BLA”) would be delayed while Humacyte remediated these deficiencies; and
- as a result, there was a substantial risk to FDA approval of Acellular Tissue Engineered Vessel (“ATEV”) for vascular trauma; and
- as a result of the foregoing, defendants’ positive statements about Humacyte’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
